Obesity

Pharma

Novo testing smaller doses of Wegovy pill in phase 3 study

Novo is pursuing further Wegovy pill optionality by kicking off OASIS 5, which is evaluating the effectiveness of two smaller doses of the oral GLP-1.

Kevin Dunleavy Aug 20, 2026 8:51am

Obesity not a winner-takes-all game, Novo CEO says: Reuters

Aug 13, 2026 11:33am

Fierce Biotech

Novo Nordisk’s CFO reflects on ‘pressure’ to drive growth

Aug 7, 2026 9:08am

Novo CEO stands firm on guidance amid Wegovy pill sales onslaught

Aug 5, 2026 11:20am

Novo Nordisk runs new obesity experience installation in London

Jul 9, 2026 9:18am

Dr. Reddy's temporarily pauses generic semaglutide supplies

Jul 9, 2026 8:48am